X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (563) 563
humans (539) 539
index medicus (377) 377
male (302) 302
prostacyclin (273) 273
epoprostenol - pharmacology (258) 258
pharmacology & pharmacy (235) 235
rats (204) 204
epoprostenol - metabolism (195) 195
epoprostenol - analogs & derivatives (183) 183
receptors, epoprostenol (161) 161
pulmonary hypertension (160) 160
mice (156) 156
female (153) 153
cells, cultured (139) 139
hypertension, pulmonary - drug therapy (137) 137
in vitro techniques (134) 134
biochemistry & molecular biology (130) 130
dose-response relationship, drug (116) 116
receptors, prostaglandin - metabolism (107) 107
cyclic amp - metabolism (106) 106
cardiac & cardiovascular systems (105) 105
expression (97) 97
pulmonary arterial hypertension (95) 95
signal transduction (94) 94
iloprost - pharmacology (91) 91
prostaglandins (87) 87
prostanoid receptors (83) 83
hypertension (82) 82
endothelium, vascular - metabolism (81) 81
nitric-oxide (81) 81
physiology (81) 81
receptor (80) 80
epoprostenol - biosynthesis (79) 79
rats, sprague-dawley (78) 78
receptors (76) 76
respiratory system (76) 76
vasodilation - drug effects (71) 71
hypertension, pulmonary - physiopathology (70) 70
cell biology (68) 68
endothelium, vascular - drug effects (68) 68
nitric oxide (67) 67
calcium - metabolism (66) 66
endothelium (66) 66
vasodilator agents - pharmacology (66) 66
double-blind (65) 65
endothelin receptor antagonists (65) 65
peripheral vascular disease (65) 65
receptors, prostaglandin - agonists (64) 64
activation (63) 63
lipids (62) 62
mice, inbred c57bl (61) 61
receptors, epoprostenol - agonists (60) 60
dinoprostone - pharmacology (59) 59
receptors, epoprostenol - metabolism (59) 59
research (59) 59
epoprostenol - physiology (57) 57
iloprost (56) 56
mice, knockout (56) 56
cell line (55) 55
endothelin receptor antagonist (55) 55
signal transduction - drug effects (55) 55
antihypertensive agents - therapeutic use (54) 54
blood platelets - metabolism (54) 54
inhibition (54) 54
cells (53) 53
muscle, smooth, vascular - drug effects (53) 53
prostacyclin receptor (53) 53
adult (52) 52
nitric oxide - metabolism (52) 52
smooth-muscle (51) 51
rabbits (49) 49
drug therapy (48) 48
physiological aspects (48) 48
platelet aggregation - drug effects (48) 48
rats, wistar (48) 48
receptors, prostaglandin - drug effects (47) 47
receptors, prostaglandin - genetics (47) 47
research article (47) 47
enzyme inhibitors - pharmacology (45) 45
smooth-muscle-cells (45) 45
endothelin (44) 44
5 inhibitor therapy (43) 43
inhaled iloprost (43) 43
time factors (43) 43
adenylyl cyclases - metabolism (42) 42
pharmacology (42) 42
phosphorylation (42) 42
platelet aggregation inhibitors - pharmacology (42) 42
prostanoids (42) 42
randomized controlled-trial (42) 42
arterial-hypertension (41) 41
epoprostenol (41) 41
medicine & public health (41) 41
receptors, prostaglandin - physiology (41) 41
vasoconstriction - drug effects (41) 41
blood platelets - drug effects (40) 40
middle aged (40) 40
epoprostenol - therapeutic use (39) 39
smooth muscle (39) 39
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Lipid Research, ISSN 0022-2275, 02/2003, Volume 44, Issue 2, pp. 271 - 279
Journal Article
Pharmacological reviews, ISSN 1521-0081, 2012, Volume 64, Issue 3, pp. 540 - 582
Prostacyclin (PGI(2)) is a member of the prostanoid group of eicosanoids that regulate homeostasis, hemostasis, smooth muscle function and inflammation.... 
MIDDLE CEREBRAL-ARTERY | MESENTERIC RESISTANCE ARTERIES | PROSTANOID RECEPTORS | ENDOTHELIAL VASODILATOR PRODUCTION | FETAL DUCTUS-ARTERIOSUS | PROSTAGLANDIN I-2 | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | PERSISTENT PULMONARY-HYPERTENSION | SMOOTH-MUSCLE-CELLS | INTRAUTERINE GROWTH RESTRICTION | Adaptation, Physiological | Vascular Diseases - prevention & control | Cytochrome P-450 Enzyme Inhibitors | Epoprostenol - biosynthesis | Humans | Cytochrome P-450 Enzyme System - metabolism | Intramolecular Oxidoreductases - antagonists & inhibitors | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Endothelium, Vascular - drug effects | Endothelium, Vascular - enzymology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Pregnancy Complications, Cardiovascular - metabolism | Receptors, Epoprostenol - agonists | Pregnancy Complications, Cardiovascular - prevention & control | Enzyme Inhibitors - chemistry | Epoprostenol - pharmacology | Female | Intramolecular Oxidoreductases - metabolism | Infant, Newborn | Receptors, Epoprostenol - metabolism | Signal Transduction | Thromboxane-A Synthase - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Vascular Diseases - enzymology | Enzyme Inhibitors - therapeutic use | Pregnancy | Receptors, Epoprostenol - antagonists & inhibitors | Epoprostenol - analogs & derivatives | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Endothelium, Vascular - metabolism | Prostaglandin-Endoperoxide Synthases - metabolism | Thromboxane-A Synthase - metabolism | Ligands | Vasodilation - drug effects | Vascular Diseases - metabolism | Pregnancy Complications, Cardiovascular - enzymology | Review
Journal Article
Journal Article
Clinical & Experimental Allergy, ISSN 0954-7894, 02/2010, Volume 40, Issue 2, pp. 317 - 326
Journal Article
Journal Article
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 09/2012, Volume 126, Issue 11, pp. 1373 - 1384
Journal Article
Diabetes, ISSN 0012-1797, 05/2016, Volume 65, Issue 5, pp. 1398 - 1409
...) receptor in pancreatic β-cells and in glomerular podocytes. The IP receptor agonist MRE-269 increased intracellular 3',5'-cyclic adenosine monophosphate (cAMP... 
Diabetes Mellitus, Experimental - drug therapy | Humans | Pyrazines - therapeutic use | Renal Insufficiency - prevention & control | Insulin-Secreting Cells - metabolism | Diabetic Nephropathies - physiopathology | Receptors, Epoprostenol - agonists | Acetamides - therapeutic use | Protein Processing, Post-Translational - drug effects | RNA Interference | Renal Insufficiency - complications | Diabetes Mellitus, Experimental - complications | Membrane Proteins - metabolism | Phosphorylation - drug effects | Diabetes Mellitus, Experimental - metabolism | Diabetic Nephropathies - prevention & control | Insulin Secretion | Hypoglycemic Agents - therapeutic use | Cell Line | Cell Survival - drug effects | Receptors, Epoprostenol - metabolism | Diabetic Nephropathies - pathology | Podocytes - metabolism | Insulin - agonists | Membrane Proteins - genetics | Diabetic Nephropathies - metabolism | Mice, Inbred C57BL | Renal Insufficiency - metabolism | Podocytes - pathology | Hypoglycemic Agents - pharmacology | Mice, Knockout | Insulin - metabolism | Podocytes - ultrastructure | Receptors, Epoprostenol - genetics | Animals | Insulin-Secreting Cells - drug effects | Membrane Proteins - antagonists & inhibitors | Podocytes - drug effects | Renal Insufficiency - pathology | Diabetes Mellitus, Experimental - pathology | Acetates - pharmacology | Prodrugs - therapeutic use | Mutation | Pyrazines - pharmacology
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2002, Volume 296, Issue 5567, pp. 539 - 541
Thromboxane (Tx) A is a vasoconstrictor and platelet agonist. Aspirin affords cardioprotection through inhibition of TxA formation by platelet cyclooxygenase (COX-1). Prostacyclin (PGI... 
Vascular system injuries | Receptors | Platelet activation | Microscopy | Pathologic constriction | Cyclooxygenase inhibitors | Agonists | Reports | Biosynthesis | Physical trauma | Platelets | Endothelium, Vascular - cytology | Epoprostenol - metabolism | Receptors, Epoprostenol | Cyclooxygenase 2 | Humans | Receptors, Prostaglandin - physiology | Endothelium, Vascular - drug effects | Male | Receptors, Thromboxane - genetics | Endothelium, Vascular - physiology | Epoprostenol - physiology | Carotid Artery, Common - physiology | Prostaglandin-Endoperoxide Synthases | Cell Division | Receptors, Thromboxane - antagonists & inhibitors | Platelet Aggregation - drug effects | Muscle, Smooth, Vascular - physiology | Sulfones | Carotid Artery Injuries - pathology | Muscle, Smooth, Vascular - drug effects | Carotid Artery, Common - cytology | Mice, Inbred C57BL | Mice, Transgenic | Lactones - adverse effects | Muscle, Smooth, Vascular - cytology | Lactones - therapeutic use | Mice, Knockout | Naphthalenes | Membrane Proteins | Animals | Cyclooxygenase 2 Inhibitors | Tunica Intima - cytology | Tetrahydronaphthalenes - pharmacology | Thromboxane A2 - physiology | Carotid Artery, Common - drug effects | Propionates | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid - pharmacology | Mice | Platelet Activation - drug effects | Receptors, Thromboxane - physiology | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Isoenzymes - antagonists & inhibitors | Proteins | Heart | Aspirin | Rodents | Cells
Journal Article